ArticleKidney international reports2023

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.

David Kavanagh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.